Contineum Therapeutics, Inc. Logo

Contineum Therapeutics, Inc.

Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.

CTNM | US

Overview

Corporate Details

ISIN(s):
US21217B1008
LEI:
Country:
United States of America
Address:
3565 GENERAL ATOMICS COURT, SUITE 200, 92121 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel, oral small molecule therapies. The company focuses on pioneering treatments for conditions at the intersection of neuroscience, inflammation, and immunology (NI&I). Its pipeline is based on clinically validated biological targets and includes a potential best-in-class LPA1R antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS), and a potential first-in-class M1R antagonist for major depressive disorder (MDD) in collaboration with a Johnson & Johnson company. Formerly Pipeline Therapeutics, Contineum aims to develop impactful treatments for serious neurological, inflammatory, and fibrotic diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Contineum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Contineum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Contineum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
Korro Bio, Inc. Logo
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
United States of America KRRO
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia KRKG

Talk to a Data Expert

Have a question? We'll get back to you promptly.